FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 10/2023”. The Monitor is a month-to-month printed overview of enterprise capital tendencies within the European Life Sciences sector.
As of the tip of October 2023 we determine the next present VC tendencies in Europe:
- In 2023, total Life Sciences funding has reached EUR 7,324m
- Biotech obtained 42% of the entire funding quantity (-3% in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotech
- AgomAb Therapeutics (Belgium) has the best transaction quantity of EUR 94m in October, adopted by MinervaX (Denmark) EUR 54m and AstronauTx (United Kingdom) EUR 54m
- The EIC Fund (automobile of the European Innovation Council, Belgium) dominates the Prime 5 Buyers (by deal quantity), adopted by Revival Healthcare Capital (United States) and Gilde Healthcare Companions (Netherlands)
- Prime 5 Offers exceed EUR 130m every, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the complete report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.